natgillin/translations-raw huggingface dataset:
In vivo hos terminale patienter, som senere gennemgik hjerneobduktion, korrelerte kvantitativt flutemetamol (18F) optag i den kortikale grå substans med β-amyloid niveauer ved brug af 4G8 anti- amyloid antistof, som farver β-amyloid i både neuritisk og i diffust plak.
In vivo, quantitative correlation was assessed in end-of-life patients between flutemetamol (18F) uptake in cortical grey matter and the total β-amyloid burden in autopsied samples using 4G8 anti-amyloid antibody that stains β-amyloid found in both neuritic and diffuse plaques.
In vivo humane undersøgelser af interaktion har påvist, at anagrelid ikke påvirker digoxins eller warfarins farmakokinetiske egenskaber.
In vivo interaction studies in humans have demonstrated that anagrelide does not affect the pharmacokinetic properties of digoxin or warfarin.
In vivo interaktionsundersøgelser hos mennesker har påvist, at digoxin og warfarin ikke påvirker anagrelids farmakokinetiske egenskaber.
In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the pharmacokinetic properties of anagrelide.
In vivo kan dolutegravir øge plasmakoncentrationen af lægemidler, for hvilke udskillelsen afhænger af OCT2 eller MATE-1 (f.eks. dofetilid, metformin) (se tabel 1 og pkt.
In vivo, dolutegravir may increase plasma concentrations of medicinal products in which excretion is dependent upon OCT2 or MATE-1 (e.g. dofetilide, metformin) (see Table 1 and section 4.3).
In vivo kan eslicarbazepin inducere metabolismen af lægemidler, der især udskilles ved konjugering via UDP-glukuronyltransferaser.
Eslicarbazepine in vivo may have an inducing effect on the metabolism of medicinal products that are mainly eliminated by conjugation through the UDP glucuronyl transferases.
In vivo kan flutemetamol (18F) påvise diffust β-amyloidplak, når disse er hyppigt forekommende.
In vivo, flutemetamol (18F) can detect β-amyloid diffuse plaques when they are frequent.
In vivo studier og populations farmakokinetiske analyser
In vivo studies and population pharmacokinetic analysis
In vivo studier og populationsfarmakokinetiske analyser
In vivo studies and population pharmacokinetic analysis
In vivo topikal okulær administration af emedastin giver en koncentrationsafhængig hæmning af den histaminstimulerede konjunktivalvaskulære permeabilitet.
In vivo topical ocular administration of emedastine produces a concentration-dependent inhibition of histamine-stimulated conjunctival vascular permeability.
In vivo topikal okulær administration af emedastin producerer en koncentrationsafhængig hæmning af den histaminstimulerede konjunktivalvaskulære permeabilitet.
In vivo topical ocular administration of emedastine produces a concentration-dependent inhibition of histamine-stimulated conjunctival vascular permeability.
In vivo var t1/2 for MTIC 1,8 timer som for TMZ.
In vivo, the t½ of MTIC was similar to that of TMZ, 1.8 hr.
In vivo – behandling af HIV: I et åbent, randomiseret, klinisk studie (GS-01-934) med antiretroviral- naive patienter blev der foretaget genotypebestemmelser på plasma-HIV 1-isolater fra alle patienter med bekræftet HIV-rna > 400 kopier/mL ved uge 48, 96 eller 144 eller på tidspunktet for tidlig seponering af forsøgsmedicinen.
In vivo - treatment of HIV-1: In an open-label randomised clinical study (GS-01-934) in antiretroviral-naïve patients, genotyping was performed on plasma HIV-1 isolates from all patients with confirmed HIV RNA > 400 copies/mL at weeks 48, 96 or 144 or at the time of early study drug discontinuation.
In vivo- og ex vivo-dyrestudier i forskellige trombose-dyremodeller har vist, at dabigatran efter intravenøs administration har antitrombotisk effekt og antikoagulerende aktivitet, og det samme er påvist for dabigatranetexilat efter oral indtagelse.
In-vivo and ex-vivo animal studies have demonstrated antithrombotic efficacy and anticoagulant activity of dabigatran after intravenous administration and of dabigatran etexilate after oral administration in various animal models of thrombosis.
In vivo- og ex vivo-dyrestudier i forskellige trombose-dyremodeller har vist, at dabigatran efter intravenøs administration har antitrombotisk effekt og antikoagulerende aktivitet, og det samme er påvist for dabigatranetexilat efter peroral indtagelse.
In-vivo and ex-vivo animal studies have demonstrated antithrombotic efficacy and anticoagulant activity of dabigatran after intravenous administration and of dabigatran etexilate after oral administration in various animal models of thrombosis.
In vivo-data
In vivo data
In vivo-forsøg har vist, at nalmefen reducerer alkoholforbruget, muligvis ved at påvirke kortikomesolimbiske funktioner.
In vivo studies have demonstrated that nalmefene reduces alcohol consumption, possibly by modulating cortico-mesolimbic functions.
In vivo-indgivelse af vandetanib reducerede tumorcelle-induceret angiogenese, permeabiliteten af tumorkar, og densiteten af tumormikrokar, samt hæmmede tumorvækst i en række humane xenograft- tumormodeller i athymiske mus.
In vivo vandetanib administration reduced tumour cell-induced angiogenesis, tumour vessel permeability, tumour microvessel density, and inhibited tumour growth of a range of human xenograft tumour models in athymic mice.
In vivo-Micronucleus-testen var negativ.
The in vivo micronucleus test was negative.
In vivo-resistens (antiretroviral-naive patienter): I et 144-ugers åbent, randomiseret, klinisk studie (GS-01-934) med antiretroviral-naive patienter, hvor efavirenz, emtricitabin og tenofovirdisoproxilfumarat blev anvendt som individuel formulering (eller som efavirenz og en fast kombination af emtricitabin og tenofovirdisoproxilfumarat (Truvada) fra uge 96 til 144), er der foretaget genotypebestemmelser på plasma-hiv-1-isolater fra alle patienter med bekræftet hiv-rna > 400 kopier/ml i uge 144 eller tidlig seponering (se afsnittet om Klinisk erfaring).
In vivo resistance (antiretroviral-naïve patients): In a 144-week open-label randomised clinical study (GS-01-934) in antiretroviral-naïve patients, where efavirenz, emtricitabine and tenofovir disoproxil fumarate were used as individual formulations (or as efavirenz and the fixed combination of emtricitabine and tenofovir disoproxil fumarate (Truvada) from week 96 to 144), genotyping was performed on plasma HIV-1 isolates from all patients with confirmed HIV RNA > 400 copies/ml at week 144 or early study drug discontinuation (see section on Clinical experience).
In vivo-undersøgelser har vist, at tylvalosin er til stede i højere koncentrationer i slimhinderne i luftvejs- og tarmvæv end i plasma.
In vivo studies have shown tylvalosin to be present in higher concentrations in the mucous lining of the respiratory and gut tissues compared to the plasma.
In vivo-undersøgelser:
In vivo studies
In vivo-vurdering af interaktioner
In vivo assessment of interactions
In vivo: Hæmning af osteoblastdannelse, direkte cytostatisk og pro-apoptotisk aktivitet på tumorceller, synergistisk cytostatisk effekt med andre anti-cancermidler, anti-adhæsion-
In vitro: Inhibition of osteoblast proliferation, direct cytostatic and pro-apoptotic activity on tumour cells, synergistic cytostatic effect with other anti-cancer drugs, anti-adhesion/invasion activity.
In vivo: Hæmning af osteoblastdannelse, direkte cytostatisk og pro-apoptotisk aktivitet på tumorceller, synergistisk cytostatisk effekt med andre anti-cancermidler, anti-adhæsion-/invasionsaktivitet.
In vitro: Inhibition of osteoblast proliferation, direct cytostatic and pro-apoptotic activity on tumour cells, synergistic cytostatic effect with other anti-cancer drugs, anti-adhesion/invasion activity.
In vivo: Hæmning af osteoblastdannelse, direkte cytostatisk og pro-apoptotisk aktivitet på tumorceller, synergistisk cytostatisk virkning med andre anti-cancermidler, anti-adhæsion-
In vitro: Inhibition of osteoblast proliferation, direct cytostatic and pro-apoptotic activity on tumour cells, synergistic cytostatic effect with other anti-cancer drugs, anti-adhesion/invasion activity.
In vivo: Hæmning af osteoklastisk knogleresorption, hvilket ændrer knoglemarvens mikromiljø og mindsker bidraget til tumorcellevæksten og den anti-angiogenetiske aktivitet.
In vivo: Inhibition of osteoclastic bone resorption, which alters the bone marrow microenvironment, making it less conducive to tumour cell growth and anti-angiogenic activity.
In vivo: Hæmning af osteoklastisk knogleresorption, hvilket ændrer knoglemarvens mikromiljø og mindsker bidraget til tumorcellevæksten, den anti-angiogenetiske aktivitet og anti-smerte aktiviteten.
In vivo: Inhibition of osteoclastic bone resorption, which alters the bone marrow microenvironment, making it less conducive to tumour cell growth and anti-angiogenic activity.
In vivo: Hæmning af osteoklastisk knogleresorption, hvilket ændrer knoglemarvens mikromiljø og mindsker bidraget til tumorcellevæksten, den anti-angiogenetiske aktivitet og anti-smerte aktiviteten.
In vivo: Inhibition of osteoclastic bone resorption, which alters the bone marrow microenvironment, making it less conducive to tumour cell growth, anti-angiogenic activity and anti-pain activity.
In vivo: Hæmning af osteoklastisk knogleresorption, hvilket ændrer knoglemarvens mikromiljø og mindsker bidraget til tumorcellevæksten, den anti-angiogenetiske aktivitet og anti-smerte aktiviteten.
In-vivo: Inhibition of osteoclastic bone resorption, which alters the bone marrow microenvironment, making it less conducive to tumour cell growth, anti-angiogenic activity and anti-pain activity.
In- vitro studier vedr. plasma protein binding viste, at den gennemsnitlige koncentration af frit, aktivt stof var 77%.
In vitro plasma protein binding studies determined that the mean concentration of the free active drug was
In-circuit oxygenmetre kan benyttes til at måle den indåndede oxygenfraktion og afhængig af det individuelle dyr, vil et niveau på 50 – 100 % af veterinærlægemidlet muligvis være krævet.
In-circuit oxygen meters can be used to measure the inspired oxygen fraction and depending on the individual animal, a level of 50 – 100 % of the veterinary medicinal product may be required.
In-ovo udstyr bør kalibreres for at sikre at en dosis på 0,05 ml anvendes til hvert æg.
In-ovo equipment should be calibrated to ensure that a 0.05 ml dose is applied to each egg.
In-vitro data: Entacapon bindes til humant albumin – bindingssted II, der også binder flere andre lægemidler, inklusive diazepam og ibuprofen.
In vitro data: Entacapone binds to human albumin binding site II which also binds several other medicinal products, including diazepam and ibuprofen.
In-vitro mærkning
in vitro labelling
In-vitro studier i humane levermikrosomer viser, at ertapenem ikke hæmmer metabolismen medieret af de 6 primære CYP-isoformer: 1A2, 2C9, 2C19, 2D6, 2E1 og 3A4.
In-vitro studies in human liver microsomes indicate that ertapenem does not inhibit metabolism mediated by any of the six major CYP isoforms: 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4.
In-vitro studier viser, at ertapenem havde en lille effekt på plasmaproteinbinding hos meget proteinbundne lægemidler (warfarin, ethinyl estradiol og norethindron).
In-vitro studies indicate that the effect of ertapenem on the plasma protein binding of highly protein bound medicinal products (warfarin, ethinyl estradiol, and norethindrone) was small.
In-vitro studier viser, at ertapenem ikke hæmmer P-glycoprotein-medieret transport af digoxin eller vinblastin og, at ertapenem ikke er et substrat for P-glycoprotein-medieret transport.
In-vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of digoxin or vinblastine and that ertapenem is not a substrate for P-glycoprotein-mediated transport.
In-vitro-binding af pomalidomid-enantiomerer til proteiner i humant plasma er i intervallet 12- 44% og er ikke koncentrationsafhængig.
In vitro binding of pomalidomide enantiomers to proteins in human plasma ranges from 12% to 44% and is not concentration dependent.
In-vitro-forsøg har påvist, at empagliflozin hverken hæmmer, inaktiverer eller inducerer CYP450- isoformer.
Based on in vitro studies, empagliflozin does not inhibit, inactivate, or induce CYP450 isoforms.
In-vivo forsøg og populationsfarmakokinetiske analyser
In vivo studies and population pharmacokinetic analysis
inaktiverede poliovira, polysakkarider (sukkerarter) fra bakterien Haemophilus influenzae type b (”Hib”, en bakterie, der forårsager meningitis).
inactivated polioviruses; polysaccharides (sugars) from the bacterium Haemophilus influenzae type b (‘Hib’, a bacterium that causes meningitis).
inaktiverede poliovira.
inactivated polioviruses.
Inaktiveret bluetongue-virus, serotype 1, stamme BTV-1/ALG2006/01 E1 RP*≥ 1 Inaktiveret bluetongue-virus, serotype 8, stamme BTV-8/BEL2006/02 RP*≥ 1
Inactivated bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP* ≥ 1 Inactivated bluetongue virus, serotype 8, strain BTV-8/BEL2006/02 RP* ≥ 1
Inaktiveret bluetongue-virus, serotype 1, stamme BTV-1/ALG2006/01 E1 RP*≥ 1 Inaktiveret bluetongue-virus, serotype 8, stamme BTV-8/BEL2006/02 RP*≥ 1
Inactivated bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP* ≥ 1, Inactivated bluetongue virus, serotype 8, strain BTV-8/BEL2006/02 RP* ≥ 1
Inaktiveret bluetonguev irus, serotype 1, stamme BTV- 1/ALG2006/
Inactivated Bluetongue Virus, serotype 1, strain BTV- 1/ALG2006/01 E1 RP* ≥ 1
Inaktiveret bluetonguevirus serotype 1 .....................................................................  1,9 log10 pixel* (*) Antigenindhold (VP2 protein) fastsat ved immuno-assay
.Inactivated Bluetongue Virus Serotype 1............................................................... 1.9 log10 pixels * (*) Antigen content (VP2 protein) by immuno-assay
Inaktiveret bluetonguevirus serotype 1 .......................................................................... 1,9 log10 pixel* (*) Antigenindhold (VP2 protein) fastsat ved immuno-assay
Inactivated Bluetongue Virus Serotype 1................................................................. 1.9 log10 pixels* (*) Antigen content (VP2 protein) by immuno-assay
Inaktiveret bluetonguevirus, serotype 1, stamme BTV-1/ALG2006/01 E1 Inaktiveret bluetonguevirus, serotype 8, stamme BTV-8/BEL2006/02
Inactivated bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1 Inactivated bluetongue virus, serotype 8, strain BTV-8/BEL2006/02
Inaktiveret bluetonguevirus, serotype 1, stamme BTV-1/ALG2006/01 E1 RP*≥ 1
Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP* ≥ 1
Inaktiveret bluetonguevirus, serotype 1, stamme BTV-1/ALG2006/01 E1 RP*≥ 1 Inaktiveret bluetonguevirus, serotype 8, stamme BTV-8/BEL2006/02 RP*≥ 1
Inactivated bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP* ≥ 1 Inactivated bluetongue virus, serotype 8, strain BTV-8/BEL2006/02 RP* ≥ 1
Inaktiveret bluetonguevirus, serotype 8, stamme BTV-8/BEL2006/02 RP* ≥ 1
Inactivated bluetongue virus, serotype 8, strain BTV-8/BEL2006/02 RP* ≥ 1
Inaktiveret bluetonguevirus, serotype 8, stamme BTV-8/BEL2006/02 RP*≥ 1
Inactivated bluetongue virus, serotype 8, strain BTV-8/BEL2006/02 RP* ≥ 1
Inaktiveret bluetonguevirus, serotype 8: 106,5 CCID50*
Bluetongue virus inactivated, serotype 8: 106.5 CCID50
Inaktiveret bluetonguevirus, serotype 8: 106,5 CCID50* (*) svarende til titer før inaktivering (log10)
Bluetongue virus inactivated, serotype 8: 106.5 CCID50* (*) equivalent to titre prior to inactivation (log10)
Inaktiveret bluetonguevirus........................................ serotypespecifik grænseværdi (log10 pixel)** (*) højst 2 forskellige inaktiverede bluetonguevirus serotyper
Inactivated Bluetongue Virus ......................................... strain specific pass level (log10 pixels) ** (*) maximum of two different inactivated bluetongue virus serotypes
Inaktiveret bluetonguevirus........................................ serotypespecifik grænseværdi (log10 pixel)** (*) højst 2 forskellige inaktiverede bluetonguevirus serotyper
Inactivated Bluetongue Virus............................................ strain specific pass level (log10 pixels)** (*) maximum of two different inactivated bluetongue virus serotypes
Inaktiveret Bordetella bronchiseptica, stamme 833CER, Rekombinant Type
Inactivated B.bronchiseptica, strain 833CER
Inaktiveret Bordetella bronchiseptica, stamme 833CER:..........................................
Inactivated Bordetella bronchiseptica, strain 833CER: .............................................
Inaktiveret Bordetella bronchiseptica, stamme 833CER:......................................9,8 BbCC(*)
Inactivated Bordetella bronchiseptica, strain 833CER: .........................................9.8 BbCC(*)
Inaktiveret Bordetella kighoste 2 mindst 4 International Units Hepatitis B overflade antigen (rDNA) 2, 3 10 microgram Haemophilus influenzae type b polysakkarid (polyribosylribitolfosfat) 2 2.5 microgram konjugeret til stivkrampe toxoid som bærestof 5-10 microgram
Inactivated Bordetella pertussis 2 not less than 4 International Units Hepatitis B surface antigen (rDNA) 2, 3 10 micrograms Haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) 2 2.5 micrograms conjugated to tetanus toxoid as a carrier 5-10 micrograms
Inaktiveret Bordetella kighoste 2 mindst 4 International Units Hepatitis B overflade antigen (rDNA) 2, 3 10 mikrogram Hæmofilus influenzae type b polysakkarid (polyribosylribitolfosfat) 2 2.5 mikrogram konjugeret til stivkrampe toxoid som bærestof 5-10 mikrogram
Inactivated Bordetella pertussis 2 not less than 4 International Units Hepatitis B surface antigen (rDNA) 2, 3 10 micrograms Haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) 2 2.5 micrograms conjugated to tetanus toxoid as a carrier 5-10 micrograms
Inaktiveret Bordetella kighoste 2  4 IU
Inactivated Bordetella pertussis 2  4 IU
Inaktiveret BTV1.............................................................................................................. 1,9 log10 pixel
Inactivated BTV 1 ....................................................................................................... 1.9 log10 pixels
Inaktiveret BTV1.............................................................................................................. 1,9 log10 pixel
Inactivated BTV 1 ...................................................................................................... 1.9 log10 pixels
Inaktiveret BTV1....................................................................................................... 1,9 log10 pixel*
Inactivated BTV1 ..................................................................................................... 1.9 log10 pixels
Inaktiveret Coxiella burnetii, stamme Nine Mile ≥72 QF enheder*
Inactivated Coxiella burnetii, strain Nine Mile > 72 QF Units
Inaktiveret Coxiella burnetii, stamme Nine Mile ≥72 QF enheder/ml
Inactivated Coxiella burnetii, strain Nine Mile > 72 QF Units/ml
Inaktiveret Coxiella burnetii, stamme Nine Mile ≥72 QF Units/ml
Inactivated Coxiella burnetii, strain Nine Mile > 72 QF Units/ml
Inaktiveret Erysipelothrix rhusiopathiae, stamme R32E11 ELISA > 3,34
Erysipelothrix rhusiopathiae, strain R32E11, ELISA > 3.34 IE50
Inaktiveret Erysipelothrix rhusiopathiae, stamme R32E11 ELISA > 3,34
Inactivated Erysipelothrix rhusiopathiae, strain R32E11, ELISA > 3.34 IE50
Inaktiveret felint panleukopenivirus, stamme CU4: R.P. 8,50 – 12,25 Inaktiveret felint calicivirus, stamme 255: R.P. 1,26 – 2,40
Inactivated feline panleukopenia virus (CU4 strain): R.P. 8.5-12.25 Inactivated feline calicivirus (255 strain): R.P. 1.26-2.40 Inactivated feline rhinotracheitis virus (605 strain): R.P. 1.
Inaktiveret felint rhinotracheitisvirus, stamme 605: R.P. 1,39 – 2,10 Inaktiveret felint Chlamydophila felis,stamme Cello: R.P. 1,69 – 3,50 Inaktiveret felint leukæmivirus, stamme 61E: R.P. 1,45 – 2,00
39-2.10 Inactivated feline Chlamydophila felis (Cello strain): R.P. 1.69-3.50 Inactivated feline leukaemia virus (61E strain): R.P. 1.45-2.00.
Inaktiveret FPV (RP 8,50 – 12,25), FCV (RP 1,26 – 2,40), FVR (RP 1,39 – 2,10), Chlam (RP 1,69 –
Inactivated FPV (RP 8.50–12.25); FCV (RP 1.26–2.40); FVR (RP 1.39–2.10); Chlam (RP 1.69–3.50); FeLV (RP 1.45–2.00).
Inaktiveret helcellesuspension af Ornithobacterium rhinotracheale serotype A, stamme B3263/91 1 x 107 celler*
Inactivated whole cell suspension of O. rhinotracheale
Inaktiveret helcellesuspension af Ornithobacterium rhinotracheale serotype A, stamme B3263/91 1 x 107 celler*
Inactivated whole cell suspension of Ornithobacterium rhinotracheale serotype A strain B3263/91 1 x 107 cells
Inaktiveret helcellesuspension af Ornithobacterium rhinotracheale serotype A, stamme B3263/91 1 x 107 celler*.
Inactivated whole cell suspension of Ornithobacterium rhinotracheale serotype A, strain B3263/91 1 x 107 cells
Inaktiveret helt fugleinfluenza-virusantigen af undertype H5N2 ((stamme A/duck/Potsdam/1402/86)), inducerer en HI titer på > 6.0 log2 som testet i henhold til potency test.
Inactivated whole avian influenza virus antigen of H5N2 subtype (strain A/duck/Potsdam/1402/86), inducing an HI titre of ≥6.0 log2 as tested according to the potency test.
Inaktiveret helt fugleinfluenza-virusantigen, subtype H7N1 (stamme, A/CK/Italy/473/99), inducerer en HI-titer på > 6.0 log2, der er testet svarende til styrketest.
Inactivated whole avian influenza virus antigen of H7N1 subtype (strain, A/CK/Italy/473/99), inducing an HI titre of ≥6.0 log2 as tested according to the potency test.
Inaktiveret helt fugleinfluenza-virusantigen, subtype H7N1 (stamme, A/CK/Italy/473/99, inducerer en HI-titer på > 6.0 log2, der er testet svarende til styrketest.
Inactivated whole avian influenza virus antigen of H7N1 subtype (strain, A/CK/Italy/473/99), inducing an HI titre of ≥6.0 log2 as tested according to the potency test.
Inaktiveret kanin hæmoragisk lidelse type 2 virus (RHDV2), stamme V-1037 ≥70% cELISA40
Inactivated rabbit haemorrhagic disease type 2 virus (RHDV2), strain V-1037 ≥70% cELISA40
Inaktiveret kanin hæmoragisk lidelse type 2 virus (RHDV2), stamme V-1037: ≥70 % cELISA40*
Inactivated rabbit haemorrhagic disease type 2 virus (RHDV2), strain V-1037: ≥70% cELISA40
Inaktiveret kimærisk flavivirus-stamme YF-WN ≥ 492 AE Iscom-Matrix
Inactivated chimeric flavivirus strain YF-WN ≥ 492 AU Iscom-Matrix
Inaktiveret kimærisk flavivirus-stamme YF-WN ≥ 492 AE1
Inactivated chimeric flavivirus strain YF-WN ≥ 492 AU1
Inaktiveret kimærisk flavivirus-stamme YF-WN ≥ 492 AE1 Iscom-Matrix indeholdende:
Inactivated chimeric flavivirus strain YF-WN ≥ 492 AU1 Iscom-Matrix containing:
Inaktiveret Leptospira Stammer*
Inactivated Leptospira strains
Inaktiveret Leptospira stammer:
3550-7100 U1
Inaktiveret Leptospira stammer:
Inactivated Leptospira strains:
inaktiveret mund-og-klovsygeantigen, min 6 kvæg PD50 pr. stamme.
Inactivated foot-and-mouth disease antigen, at least 6 cattle PD50 per strain.
Inaktiveret mund-og-klovsygeantigener bliver renset og indeholder ikke tilstrækkelige mængder af ikke-strukturerede proteiner (NSP) til at inducere et antistofsvar efter administration af en trivalent vaccine, der indeholder en antigenmængde, svarende til mindst 15 PD50 pr stamme pr. dosis på 2 ml.
Inactivated foot-and-mouth disease antigens are purified and do not contain sufficient amounts of non-structural proteins (NSP) to induce an antibody response following administration of a trivalent vaccine containing an amount of antigen corresponding with at least 15 PD50 per strain per dose of 2 ml.
Inaktiveret Mycoplasma hyopneumoniae, stamme P-5722-3
Inactivated Mycoplasma hyopneumoniae strain P-5722-3
Inaktiveret poliomyelitisvaccine (IPV)
Inactivated poliomyelitis vaccine (IPV)
Inaktiveret poliovirus af type 1 40 DE
Inactivated type 1 poliovirus 40 DU
Inaktiveret poliovirus af type 2 8 DE
Inactivated type 2 poliovirus 8 DU
Inaktiveret poliovirus af type 2 8 DU
Inactivated type 2 Poliovirus 8 DU
Inaktiveret poliovirus af type 3 32 DU
Inactivated type 3 Poliovirus 32 DU
Inaktiveret poliovirus type 1 ...................................................................
Inactivated type 1 poliovirus ..................................................................
Inaktiveret poliovirus type 2 ...................................................................
Inactivated type 2 poliovirus ..................................................................